The initiative is part of the company's efforts to expand the use of brain MRI technology across various healthcare settings.

Breast cancer is the most commonly diagnosed form of cancer in the world among women, with more than 2.3 million cases a year ...

Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM ...

A study in the Journal of Orthopaedic Research uses a noninvasive, nonradioactive imaging-based method to measure the ...

Mass General Brigham AI and the University of Wisconsin–Madison will help to refine the company's latest foundational MRI ...

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...

LONDON, GREATER LONDON, UNITED KINGDOM, October 13, 2025 /EINPresswire.com/ -- Magnetic Resonance Imaging (MRI) Guided And Focused Ultrasound Devices Market Growth Forecast: What To Expect By 2025? In ...

A study in the Journal of Orthopaedic Research uses a noninvasive, nonradioactive imaging-based method to measure the ...

The innovation, known as the continuous delivery of cryogen-free xenon system, enables scientists to produce and maintain ...

This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...

Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...

Non-invasive device worn on the forehead uses laser technology and an array of detectors, and could form the basis of methods for monitoring brain blood flow.